Document:

exhibit4-2.htm

    EXHIBIT 4.2

     

    COMMON STOCK PURCHASE
AGREEMENT

     

    THIS COMMON
STOCK PURCHASE AGREEMENT (“Agreement”) is made and entered into as of August 16,
2010 (the “Effective
Date”),
by and between GERON CORPORATION, a Delaware corporation having its principal
place of business at 230 Constitution Drive, Menlo Park, California 94025
(“Geron”), and Samchully Pharm. Co., Ltd., having a principal place of business
at 7F MSA Bldg., 891-43 Daechi-dong Gangnam-gu Seoul, Korea 135-840
(“Manufacturer”).

     

    
      	      	A.	      	Geron and Manufacturer are the parties to that certain Master
      Manufacturing Agreement dated as of March 9, 2005 (the “Manufacturing
      Agreement”), and related Addendum Agreements (“Addendum
      Agreement”) under which Geron has agreed to purchase certain products and
      services from Manufacturer and Manufacturer has agreed to supply such
      products and services to Geron on the terms set forth
therein.
	
            	 
	
            	B.	 	Pursuant to the First Amendment to the Manufacturing Agreement,
      dated as of May 12, 2008, Geron is entitled to pay the purchase price of
      products and services by delivery of shares of Geron’s Common Stock (the
      “Shares”).

    

     

    THE PARTIES AGREE AS
FOLLOWS:

     

    
      	1.	
            	ISSUANCE OF SHARES;
      ADJUSTMENTS
	 
	 	
            	As payment of the costs for
      activities to be performed pursuant to Addendum Agreement No. 13, Geron
      will issue and deliver certificates for 115,779 Shares. Upon issuance and
      delivery of the certificate(s) for the Shares, all Shares shall be duly
      authorized and validly issued and represent fully paid shares of Geron’s
      Common Stock.
	 
	2.	
            	CLOSING;
    DELIVERY
	 
	 	      	2.1	      	The consummation of the
      transaction contemplated by this Agreement (a “Closing”) shall be held at such time
      and place as is mutually agreed upon between the parties, but in any event
      Geron shall make commercially reasonable efforts to accomplish the Closing
      no later than five (5) business days after the Effective Date hereof (the
      “Closing
      Date”). At the Closing, Geron shall deliver to Manufacturer one or more
      certificates representing all of the Shares, which Shares shall be issued
      in the name of Manufacturer or its designee and in such denominations as
      Manufacturer shall specify.
	 
	 	
            	2.2	
            	Geron’s obligations to issue
      and deliver the stock certificate(s) representing the Shares to
      Manufacturer at the Closing shall be subject to the following conditions,
      which may be waived by Geron:
	 
	 	
            	 	
            	2.2.1	      	the covenants and obligations that Manufacturer is required to
      perform or to comply with pursuant to this Agreement, at or prior to the
      Closing, must have been duly performed and complied with in all material
      respects; and
	 
	 	
            	 	
            	2.2.2	
            	the representations and warranties made by Manufacturer herein
      shall be true and correct in all material respects as of the Closing
      Date.
	 
	 	
            	2.3	
            	Manufacturer’s obligation to
      accept delivery of the stock certificate(s) representing the Shares at the
      Closing shall be subject to the following conditions, any one or more of
      which may be waived by Manufacturer:
	 
	 	
            	 	
            	2.3.1	
            	the covenants and obligations that Geron is required to perform or
      to comply with pursuant to this Agreement, at or prior to the Closing,
      must have been duly performed and complied with in all material
      respects;

    

    

    
    

    
      	
            	      	
            	      	2.3.2	      	Geron shall have available under its
      Certificate of Incorporation sufficient authorized shares of Common Stock
      to issue the Shares to Manufacturer; and
	 
	 	
            	 	
            	2.3.3	
            	the
      representation and warranties made by Geron herein shall be true and
      correct in all material respects as of the Closing Date.
	 
	3.	
            	RESTRICTIONS ON RESALE OF
      SHARES
	 
	 	
            	3.1	
            	Legends. Manufacturer understands and
      acknowledges that the Shares are not registered under the Securities Act of 1933 (the “Act”), and that under the Act and
      other applicable laws Manufacturer may be required to hold such Shares for
      an indefinite period of time. Each stock certificate representing Shares
      shall bear the following legends:
	 
	 	
            	 	
            	
              “THE
      SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
      SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). ANY TRANSFER OF SUCH
      SECURITIES SHALL BE INVALID UNLESS A REGISTRATION STATEMENT UNDER THE ACT
      IS IN EFFECT AS TO SUCH TRANSFER OR, IN THE OPINION OF COUNSEL REASONABLY
      ACCEPTABLE TO GERON, SUCH REGISTRATION IS UNNECESSARY FOR SUCH TRANSFER TO
      COMPLY WITH THE ACT. THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO THE
      TERMS OF THE COMMON STOCK PURCHASE AGREEMENT BY AND BETWEEN GERON AND
      MANUFACTURER DATED AS OF AUGUST 16, 2010. A COPY OF THE AGREEMENT CAN BE
      OBTAINED FROM THE SECRETARY OF GERON.”

            
	 
	 	
            	3.2	
            	Limits on
      Sales.
      Manufacturer agrees that if it decides to resell some or all of the
      Shares, it will do so only through orderly sales executed through a
      top-tier brokerage house, and in an appropriate manner based upon whether
      the shares are registered or unregistered, i.e., on the Nasdaq Global Market or
      in a Rule 144 compliant transaction. Manufacturer further agrees that it
      will not engage in short selling with respect to the Shares.
	 
	 	
            	3.3	
            	Further
      Limitations. Geron shall not be required (i) to transfer on its books any
      Shares that have been sold or otherwise transferred in violation of any of
      the provisions of this Agreement or applicable securities laws; or (ii) to
      treat as owner of such Shares or to accord the right to vote or pay
      dividends to any purchaser or other transferee to whom such Shares shall
      have been so transferred in violation of any of the provisions of this
      Agreement or applicable securities laws.
	 
	4.	
            	REGISTRATION
      RIGHTS
	 
	 	
            	4.1	
            	Geron agrees to make commercially reasonable efforts to file with
      the Securities and Exchange Commission (the “Commission”) within ten (10) business
      days after the Closing Date, a registration statement under the Act (the
      “Registration
      Statement”), on Form S-3 or other
      appropriate form, so as to permit a non-underwritten public offering and
      resale of the Shares under the Act by Manufacturer. Geron agrees to
      diligently pursue making the Registration Statement effective. Geron will
      make commercially reasonable efforts to notify Manufacturer of the
      effectiveness of the Registration Statement within one (1) business day of
      receiving notice from the Commission declaring the registration statement
      effective.
	 
	 	
            	4.2	
            	Geron will make commercially reasonable efforts to maintain the
      Registration Statement and any post-effective amendment thereto filed
      under this Section 4 effective under the Act until the earliest of (i) the
      date that none of the Shares covered by such Registration Statement are
      issued and outstanding, (ii) the date that all of the Shares have been
      sold pursuant to such Registration Statement, (iii) the date Manufacturer
      receives an opinion of counsel from Geron, which counsel shall be
      reasonably acceptable to Manufacturer, that the Shares may be sold under
      the provisions of Rule 144 or any similar provision then in effect under
      the Act without limitation as to volume, or (iv) the date that all Shares
      have been otherwise transferred to persons who may trade such shares
      without restriction under the Act, and Geron has delivered a new
      certificate or other evidence of ownership for such securities not bearing
      a restrictive legend.

    

    

    
    

    
      	 	
            	4.3	
            	Geron, at its expense, shall furnish to Manufacturer with respect
      to the Shares registered under the Registration Statement such reasonable
      number of copies of the Registration Statement, prospectuses and
      preliminary prospectuses in conformity with the requirements of the Act
      and such other documents as Manufacturer may reasonably request, in order
      to facilitate the public sale or other disposition of all or any of the
      Shares by Manufacturer, provided, however, that the obligation of Geron to
      deliver copies of prospectuses or preliminary prospectuses to Manufacturer
      shall be subject to the receipt by Geron of reasonable assurances from
      Manufacturer that Manufacturer will comply with the applicable provisions
      of the Act and of such other securities or blue sky laws as may be
      applicable in connection with any use of such prospectuses or preliminary
      prospectuses.
	 
	 	
            	4.4	
            	All fees, disbursements and out-of-pocket expenses and costs
      incurred by Geron in connection with the preparation and filing of the
      Registration Statement under Section 4.1 and in complying with applicable
      securities and Blue Sky laws (including, without limitation, all
      attorneys' fees of Geron) shall be borne by Geron. Manufacturer shall bear
      the cost of all fees and expenses of Manufacturer’s counsel.
	 
	 	
            	4.5	
            	Geron will advise Manufacturer promptly after it shall receive
      notice or obtain knowledge of the issuance of any stop order by the
      Commission delaying or suspending the effectiveness of the Registration
      Statement or of the initiation of any proceeding for that purpose, and
      Geron will use its commercially reasonable efforts to prevent the issuance
      of any stop order or to obtain its withdrawal at the earliest possible
      moment if such stop order should be issued.
	 
	 	
            	4.6	
            	With a view to making available to Manufacturer the benefits of
      Rule 144 (or its successor rule) and any other rule or regulation of the
      Commission that may at the time permit Manufacturer to sell the Shares to
      the public without registration, Geron covenants and agrees to make
      commercially reasonable efforts to: (i) make and keep public information
      available, as those terms are understood and defined in Rule 144, until
      the earliest of (A) such date as all of the Shares may be resold pursuant
      to Rule 144 or any other rule of similar effect or (B) such date as all of
      the Shares shall have been resold; and (ii) file with the Commission in a
      timely manner all reports and other documents required of Geron under the
      Act and under the Securities Exchange Act of 1934, as amended (the
      “Exchange
      Act”).
	 
	   	      	4.7	      	Manufacturer will cooperate with Geron in all respects in
      connection with this Agreement, including timely supplying all information
      reasonably requested by Geron (which shall include all information
      regarding Manufacturer and proposed manner of sale of the Shares required
      to be disclosed in any Registration Statement) and executing and returning
      all documents reasonably requested in connection with the registration and
      sale of the Shares and entering into and performing their obligations
      under any underwriting agreement, if the offering is an underwritten
      offering, in usual and customary form, with the managing underwriter or
      underwriters of such underwritten offering. Nothing in this Agreement
      shall obligate Manufacturer to consent to be named as an underwriter in
      any Registration Statement.

    

    

    
    

    
      	5.	      	
            	      	INDEMNIFICATION
	
            	
            	 	
            	
            
	
            	
            	5.1	
            	Geron agrees to indemnify and hold harmless Manufacturer (and each
      person, if any, who controls Manufacturer within the meaning of Section 15
      of the Act, and each officer and director of Manufacturer) against any and
      all losses, claims, damages or liabilities (or actions or proceedings in
      respect thereof), joint or several, directly or indirectly based upon or
      arising out of (i) any untrue statement or alleged untrue statement of any
      material fact contained in the Registration Statement, any preliminary
      prospectus, final prospectus or summary prospectus contained therein or
      used in connection with the offering of the Shares, or any amendment or
      supplement thereto, or (ii) any omission or alleged omission to state a
      material fact required to be stated therein or necessary to make the
      statements therein not misleading; and Geron will reimburse each such
      indemnified party for any legal or any other expenses reasonably incurred
      by them in connection with investigating, preparing, pursuing or defending
      any such loss, claim, damage, liability, action or proceeding, except
      insofar as any such loss, claim, damage, liability, action, proceeding or
      expense arises out of or is based upon (A) an untrue statement or alleged
      untrue statement or omission or alleged omission made in the Registration
      Statement, any such preliminary prospectus, final prospectus, summary
      prospectus, amendment or supplement in reliance upon and in conformity
      with written information furnished to Geron by or on behalf of
      Manufacturer or such other person expressly for use in the preparation
      thereof, (B) the failure of Manufacturer to comply with its covenants and
      agreements contained in Sections 7.1 or 7.5.3 hereof or (C) any
      misstatement or omission in any prospectus that is corrected in any
      subsequent prospectus that was delivered to Manufacturer prior to the
      pertinent sale or sales by Manufacturer. Such indemnity shall remain in
      full force and effect, regardless of any investigation made by such
      indemnified party and shall survive the transfer of the Shares by
      Manufacturer.
	
            	
            	 
	
            	
            	5.2	
            	Manufacturer agrees to indemnify and hold harmless Geron (and each
      person, if any, who controls Geron within the meaning of Section 15 of the
      Act, and each officer and director of Geron) from and against losses,
      claims, damages or liabilities (or actions or proceedings in respect
      thereof), joint or several, directly or indirectly based upon or arising
      out of, (i) any failure of Manufacturer to comply with the covenants and
      agreements contained in Sections 7.1 and 7.5.3 hereof or (ii) any untrue
      statement of a material fact contained in the Registration Statement or
      any omission of a material fact required to be stated in the Registration
      Statement or necessary in order to make the statements in the Registration
      Statement not misleading if such untrue statement or omission was made in
      reliance upon and in conformity with written information furnished to
      Geron by or on behalf of Manufacturer specifically for use in preparation
      of the Registration Statement; provided, however, that Manufacturer shall
      not be liable in any such case for (A) any untrue statement or omission in
      the Registration Statement, prospectus, or other such document which
      statement is corrected by Manufacturer and delivered to Geron prior to the
      sale from which such loss occurred, (B) any untrue statement or omission
      in any prospectus which is corrected by Manufacturer in any subsequent
      prospectus, or supplement or amendment thereto, and delivered to Geron
      prior to the sale or sales from which a loss or liability arose, or (C)
      any failure by Geron to fulfill any of its obligations under Section 5.1
      hereof.
	
            	
            	 
	
            	
            	5.3	
            	Promptly after receipt by any indemnified person of a notice of a
      claim or the beginning of any action in respect of which indemnity is to
      be sought against an indemnifying person pursuant to this Section 5, such
      indemnified person shall notify the indemnifying person in writing of such
      claim or of the commencement of such action, but the omission to so notify
      the indemnifying party will not relieve it from any liability which it may
      have to any indemnified party under this Section 5 (except to the extent
      that such omission materially and adversely affects the indemnifying
      party’s ability to defend such action) or from any liability otherwise
      than under this Section 5. Subject to the provisions hereinafter stated,
      in case any such action shall be brought against an indemnified person,
      the indemnifying person shall be entitled to participate therein, and, to
      the extent that it shall elect by written notice delivered to the
      indemnified party promptly after receiving the aforesaid notice from such
      indemnified party, shall be entitled to assume the defense thereof, with
      counsel reasonably satisfactory to such indemnified person. After notice
      from the indemnifying person to such indemnified person of its election to
      assume the defense thereof, such indemnifying person shall not be liable
      to such indemnified person for any legal expense subsequently incurred by
      such indemnified person in connection with the defense thereof, provided,
      however, that if there exists or shall exist a conflict of interest that
      would make inappropriate, in the reasonable opinion of counsel to the
      indemnified person, for the same counsel to represent both the indemnified
      person and such indemnifying person or any affiliate or associate thereof,
      the indemnified person shall be entitled to retain its own counsel at the
      expense of such indemnifying person; provided, however, that no
      indemnifying person shall be responsible for the fees and expenses of more
      than one separate counsel (together with appropriate local counsel) for
      all indemnified parties. In no event shall any indemnifying person be
      liable in respect to any amounts paid in settlement of any action unless
      the indemnifying person shall have approved the terms of such settlement.
      No indemnifying person shall, without the prior written consent of the
      indemnified person, effect any settlement of any pending or threatened
      proceeding in respect of which any indemnified person is or could have
      been a party and indemnification could have been sought hereunder by such
      indemnified person, unless such settlement includes an unconditional
      release of such indemnified person from all liability on claims that are
      the subject matter of such
proceeding.

    

    

    
    

    
      	 	
            	5.4	
            	The provisions of this Section 5 shall survive the termination of
      this Agreement.
	 
	6.	
            	REPRESENTATIONS AND
      ACKNOWLEDGEMENT OF GERON
	 
	 	
            	Geron hereby represents,
      warrants and covenants to Manufacturer as follows:
	 
	 	      	6.1	      	Organization, Good Standing
      and Qualification. Geron is a corporation duly organized, validly existing and in
      good standing under the laws of the State of Delaware and has all
      requisite corporate power and authority to carry on its business as now
      conducted and as presently proposed to be conducted. Geron is duly
      qualified to transact business and is in good standing as a foreign
      corporation in each jurisdiction in which the failure to so qualify would
      have a material adverse effect on its business or properties.
	 
	 	
            	6.2	
            	Authorization. All corporate action on the
      part of Geron, its officers, directors and stockholders necessary for the
      authorization, execution and delivery of this Agreement, the performance
      of all obligations of Geron hereunder and the authorization, issuance and
      delivery of the Shares has been taken or will be taken prior to the
      Closing, and this Agreement, when executed and delivered will constitute
      valid and legally binding obligations of Geron, enforceable against Geron
      in accordance with its terms, except as limited by applicable bankruptcy,
      insolvency, reorganization, moratorium, fraudulent conveyance and other
      laws of general application affecting enforcement of creditors’ rights
      generally, as limited by laws relating to the availability of specific
      performance, injunctive relief or other equitable remedies.
	 
	 	
            	6.3	
            	Valid Issuance of Common
      Stock. The
      Shares, when issued, sold and delivered in accordance with the terms
      hereof for the consideration expressed herein, will be duly and validly
      authorized and issued, fully paid and nonassessable and free of
      restrictions on transfer other than restrictions on transfer under this
      Agreement and applicable state and federal securities laws.
	 
	 	
            	6.4	
            	Legal Proceedings and
      Orders.
      There is no action, suit, proceeding or investigation pending or
      threatened against Geron that questions the validity of this Agreement or
      the right of Geron to enter into this Agreement or to consummate the
      transactions contemplated hereby, nor is Geron aware of any basis for any
      of the foregoing. Geron is neither a party nor subject to the provisions
      of any order, writ, injunction, judgment or decree of any court or
      government agency or instrumentality that would affect the ability of
      Geron to enter into this Agreement or to consummate the transactions
      contemplated hereby.
	 
	7.	
            	REPRESENTATIONS AND
      ACKNOWLEDGEMENTS OF MANUFACTURER
	 
	 	
            	Manufacturer hereby
      represents, warrants, acknowledges and agrees that:
	 
	 	
            	7.1	 	Investment. Manufacturer is acquiring the
      Shares for Manufacturer’s own account, and not directly or indirectly for
      the account of any other person. Manufacturer is acquiring the Shares for
      investment and not with a view to distribution or resale thereof, except
      in compliance with the Act and any applicable state law regulating
      securities.

    

    

    
    

    
      	7.2	
            	Access to Information.
      Manufacturer has consulted with its own attorney, accountant, or
      investment advisor as Manufacturer has deemed advisable with respect to
      the investment and has determined its suitability for Manufacturer.
      Manufacturer has had the opportunity to ask questions of, and to receive
      answers from, appropriate executive officers of Geron with respect to the
      terms and conditions of the transactions contemplated hereby and with
      respect to the business, affairs, financial condition and results of
      operations of Geron. Manufacturer has had access to such financial and
      other information as is necessary in order for Manufacturer to make a
      fully informed decision as to investment in Geron, and has had the
      opportunity to obtain any additional information necessary to verify any
      of such information to which Manufacturer has had access. Manufacturer
      acknowledges that neither Geron nor any of its officers, directors,
      employees, agents, representatives, or advisors have made any
      representation or warranty other than those specifically expressed
      herein.
	 
	7.3	
            	Business and Financial
      Expertise. Manufacturer further represents and warrants that it has such
      business or financial expertise as to be able to evaluate its investment
      in Geron and purchase of the Shares.
	 
	7.4	
            	Speculative Investment.
      Manufacturer acknowledges that the investment in Geron represented
      by the Shares is highly speculative in nature and is subject to a high
      degree of risk of loss in whole or in part; the amount of such investment
      is within Manufacturer’s risk capital means and is not so great in
      relation to Manufacturer’s total financial resources as would jeopardize
      the personal financial needs of Manufacturer in the event such investment
      were lost in whole or in part.
	 
	7.5	
            	Unregistered Securities.
      Manufacturer acknowledges that:
	 
	 	      	7.5.1	      	Manufacturer must bear the economic risk of investment for an
      indefinite period of time because the Shares have not been registered
      under the Act and therefore cannot and will not be sold unless they are
      subsequently registered under the Act or an exemption from such
      registration is available. Geron has made no agreements, covenants or
      undertakings whatsoever to register any of the Shares under the Act,
      except as provided in Section 4 above. Geron has made no representations,
      warranties or covenants whatsoever as to whether any exemption from the
      Act, including, without limitation, any exemption for limited sales in
      routine brokers’ transactions pursuant to Rule 144 under the Act, will
      become available and any such exemption pursuant to Rule 144, if available
      at all, will not be available unless: (i) a public trading market then
      exists in Geron’s common stock, (ii) Geron has complied with the
      information requirements of Rule 144, and (iii) all other terms and
      conditions of Rule 144 have been satisfied.
	 
	 	
            	7.5.2	
            	Transfer of the Shares has not been registered or qualified under
      any applicable state law regulating securities and, therefore, the Shares
      cannot and will not be sold unless they are subsequently registered or
      qualified under any such act or an exemption therefrom is available. Geron
      has made no agreements, covenants or undertakings whatsoever to register
      or qualify any of the Shares under any such act. Geron has made no
      representations, warranties or covenants whatsoever as to whether any
      exemption from any such act will become available.
	 
	 	
            	7.5.3	
            	Manufacturer hereby certifies that it is an “Accredited
      Investor” as that term is defined in Rule 501 under the Act.
	 
	7.6	
            	Authorization. Manufacturer has full right,
      power, authority and capacity to enter into this Agreement and to
      consummate the transactions contemplated hereby and thereby and has taken
      all necessary action to authorize the execution, delivery and performance
      of this Agreement. Upon execution and delivery, this Agreement will
      constitute a valid and binding obligation of Manufacturer enforceable
      against Manufacturer in accordance with its terms, except as such
      enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
      moratorium, fraudulent transfer, liquidation or similar laws relating to,
      or affecting generally, the enforcement of creditor's rights and remedies
      or by other equitable principles of general application from time to time
      in effect.

    

    

    
    

     

    
      	8.	      	TAX ADVICE. Manufacturer acknowledges
      that Manufacturer has not relied and will not rely upon Geron or Geron’s
      counsel with respect to any tax consequences related to the ownership,
      purchase, or disposition of the Shares. Manufacturer assumes full
      responsibility for all such consequences and for the preparation and
      filing of all tax returns and elections which may or must be filed in
      connection with the Shares. 
	 
	9.	
            	NOTICES. Any notice or other
      communication required or permitted hereunder shall be in writing and
      shall be deemed to have been duly given on the date of delivery if
      delivered personally or by facsimile, or one day, not including Saturdays,
      Sundays, or national holidays, after sending if sent by national overnight
      delivery service, or five days, not including Saturdays, Sundays, or
      national holidays, after mailing if mailed by first class United States
      mail, certified or registered with return receipt requested, postage
      prepaid, and addressed as follows: 

    

    
      	To Geron at:	Geron Corporation
	  	230 Constitution
    Drive
	  	Menlo Park, California
      94025
	 	Attention: Senior Director,
      Legal
	  	Telephone:       	(650) 473-7700
	  	Facsimile:	(650) 473-7750
	   
	To Manufacturer at:	Kris S. Choi
	  	General Manager,
	  	Marketing and Business
      Development
	  	8F Samtan Bldg.
	  	Samchully Pharm. Co.,
      Ltd.
	  	947-7, Daechi-dong,
      Gangnam-gu
	  	Seoul, Korea
  135-735
	  	e-mail:
      choicsw@samchullypharm.com
	  	Telephone:	+82 (0)2-527-6329
	  	Facsimile:	+82
  (0)2-561-6006

    

    
      	10.	
            	BINDING EFFECT.
      This
      Agreement shall be binding upon the heirs, legal representatives and
      successors of Geron and of Manufacturer; provided, however, that
      Manufacturer may not assign any rights or obligations under this
      Agreement.
	 
	11.	
            	GOVERNING
      LAW. This
      Agreement shall be governed by and construed in accordance with the laws
      of the State of California.
	 
	12.	      	INVALID PROVISIONS.
      In the
      event that any provision of this Agreement is found to be invalid or
      otherwise unenforceable by a court or other tribunal of competent
      jurisdiction, such invalidity or unenforceability shall not be construed
      as rendering any other provision contained herein invalid or
      unenforceable, and all such other provisions shall be given full force and
      effect to the same extent as though the invalid and unenforceable
      provision was not contained herein.
	 
	13.	
            	COUNTERPARTS.
      This
      Agreement may be executed in any number of identical counterparts, each of
      which shall be deemed an original, but all of which together shall
      constitute one and the same instrument.
	 
	14.	
            	AMENDMENTS. This Agreement or any
      provision hereof may be changed, waived, or terminated only by a statement
      in writing signed by the party against whom such change, waiver or
      termination is sought to be enforced.

    

    

    
    

    
      	15.	
            	FUTURE
      COOPERATION. Each
      of the parties hereto agrees to cooperate at all times from and after the
      date hereof with respect to all of the matters described herein, and to
      execute such further assignments, releases, assumptions, amendments
      of the Agreement, notifications and other documents as may be reasonably
      requested for the purpose of giving effect to, or evidencing or giving
      notice of, the transactions contemplated by this Agreement.
	 
	16.	      	ENTIRE
      AGREEMENT.
      This Agreement and the Manufacturing Agreement, including all Addenda
      thereto, constitute the entire agreement of the parties pertaining to the
      Shares and supersede all prior and contemporaneous agreements,
      representations, and understandings of the parties with respect
      thereto.

    

     

    *SIGNATURES
BEGIN ON NEXT PAGE* 

     

    

    
    

         IN WITNESS WHEREOF, the parties
hereto have executed this Common Stock Purchase Agreement as of the date first
above written. 

     

    
      	Geron
    Corporation
	 
	/s/ David L.
      Greenwood
	By:	David L.
Greenwood
	Title:       	Executive Vice
    President
	 	Chief Financial
    Officer
	
            	Treasurer and
    Secretary
	   
	Date:	
            
	  
	Samchully Pharm. Co.,
      Ltd.
	 
	/s/ Geun-Jho
      Lim Ph.D.
	By:	Geun-Jho Lim
Ph.D.
	Title:	President &
  CEO
	 
	Date:exhibit4-3.htm

    EXHIBIT 4.3 

     

    COMMON STOCK PURCHASE AGREEMENT

     

    
      	 	

              THIS COMMON STOCK
      PURCHASE AGREEMENT (“Agreement”) is made and entered into as of August 16,
      2010 (the “Effective Date”), by and between GERON
      CORPORATION, a Delaware corporation having its principal place of business
      at 230 Constitution Drive, Menlo Park, California 94025 (“Geron”), and MPI
      Research, Inc., a Michigan corporation having its principal place of
      business at 54943 North Main Street, Mattawan, MI 49071 (“MPI”).
      

            
	 	 	 	 
	
            	A.	      	Geron
      and MPI are the parties to that certain Master Agreement dated as of
      December 12, 2003 (the “Master
      Agreement”), and related Services Agreement Addenda under which
      Geron and MPI have agreed that MPI will perform certain services on behalf
      of Geron on the terms set forth therein.
	
            	 
	
            	B.	
            	Pursuant to the seventh amendment to the Master Agreement, dated
      July 30, 2010 (“Amendment No. 7”) and the eighth amendment to the Master
      Agreement, dated August 13, 2010 (“Amendment No. 8”), Geron may pay for
      the price of services performed by MPI under the Master Agreement by
      delivery of shares of Geron’s Common Stock (the “Shares”).
	
            	 
	
            	C.	
            	Geron
      has elected to make payment for such services performed pursuant to
      Amendment No. 7 and Amendment No. 8 through the delivery of Shares,
      pursuant to the terms and conditions of Amendment No. 7, Amendment No. 8
      and this Agreement.

    

     

    THE PARTIES AGREE AS FOLLOWS:

     

    
      	1.	
            	ISSUANCE OF SHARES;
      ADJUSTMENTS.
	 
	 	      	1.1	
            	As payment of the price specified in Amendment No. 7 and Amendment
      No. 8, Geron will issue and deliver certificates for 158,912 Shares. Upon
      issuance and delivery of the certificate(s) for the Shares, all Shares
      shall be duly authorized and validly issued and represent fully paid
      shares of Geron’s Common Stock.
	 
	2.	
            	CLOSING;
      DELIVERY.
	 
	 	
            	2.1	      	The consummation of the transaction contemplated by this Agreement
      (a “Closing”) shall be held at such time and place as is mutually agreed
      upon between the parties, but in any event Geron shall make commercially
      reasonable efforts to accomplish the Closing no later than five (5)
      business days after the Effective Date hereof (the “Closing Date”). At the
      Closing, Geron shall deliver to MPI one or more certificates representing
      all of the Shares, which Shares shall be issued in the name of MPI or its
      designee and in such denominations as MPI shall specify.
	 
	 	
            	2.2	
            	Geron’s obligations to issue and deliver the stock certificate(s)
      representing the Shares to MPI at the Closing shall be subject to the
      following conditions, which may be waived by Geron:
	 
	 	
            	 	
            	2.2.1	      	the
      covenants and obligations that MPI is required to perform or to comply
      with pursuant to this Agreement, at or prior to the Closing, must have
      been duly performed and complied with in all material respects;
    and
	 
	 	
            	 	
            	2.2.2	
            	the
      representations and warranties made by MPI herein shall be true and
      correct in all material respects as of the Closing
  Date.

    

    

    
    

    
      	 	
            	2.3	
            	MPI’s obligation to accept delivery of the stock certificate(s)
      representing the Shares at the Closing shall be subject to the following
      conditions, any one or more of which may be waived by MPI:
	 
	 	
            	 	
            	2.3.1	      	the
      covenants and obligations that Geron is required to perform or to comply
      with pursuant to this Agreement, at or prior to the Closing, must have
      been duly performed and complied with in all material
  respects;
	 
	 	
            	 	
            	2.3.2	
            	Geron
      shall have available under its Certificate of Incorporation sufficient
      authorized shares of Common Stock to issue the Shares to MPI;
  and
	 
	 	
            	 	
            	2.3.3	
            	the
      representation and warranties made by Geron herein shall be true and
      correct in all material respects as of any Closing Date.
	 
	3.	
            	RESTRICTIONS ON RESALE OF
      SHARES.
	 
	 	
            	3.1	
            	Legends. MPI understands and
      acknowledges that the Shares are not registered under the Securities Act
      of 1933 (the “Act”), and that under the Act and other applicable laws MPI
      may be required to hold such Shares for an indefinite period of time. Each
      stock certificate representing Shares shall bear the following
      legends:
	 
	 	      	 	      	“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER
      THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). ANY TRANSFER OF SUCH
      SECURITIES SHALL BE INVALID UNLESS A REGISTRATION STATEMENT UNDER THE ACT
      IS IN EFFECT AS TO SUCH TRANSFER OR, IN THE OPINION OF COUNSEL REASONABLY
      ACCEPTABLE TO GERON, SUCH REGISTRATION IS UNNECESSARY FOR SUCH TRANSFER TO
      COMPLY WITH THE ACT. THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO THE
      TERMS OF THE COMMON STOCK PURCHASE AGREEMENT, DATED AS OF AUGUST 16, 2010.
      A COPY OF THE AGREEMENT CAN BE OBTAINED FROM THE SECRETARY OF
      GERON.”
	 
	 	
            	3.2	
            	Limits on
      Sales. MPI
      agrees that if it decides to resell some or all of the Shares, it will do
      so only through orderly sales executed through a top-tier brokerage house,
      and in an appropriate manner based upon whether the shares are registered
      or unregistered, i.e., on the Nasdaq Global Market or in a Rule 144A
      compliant transaction. MPI further agrees that it will not engage in short
      selling with respect to the Stock.
	 
	4.	
            	REGISTRATION
      RIGHTS
	 
	 	
            	4.1	
            	Geron agrees to make commercially reasonable efforts to file with
      the Securities and Exchange Commission (the “Commission”) within ten (10)
      business days after the Closing Date, a registration statement under the
      Act (the “Registration Statement”), on Form S-3 or other appropriate form,
      so as to permit a non-underwritten public offering and resale of the
      Shares under the Act by MPI. Geron agrees to diligently pursue making the
      Registration Statement effective. Geron will notify MPI of the
      effectiveness of the Registration Statement within one (1) business day of
      receiving notice from the Commission.

    

    

    
    

    
      	
            	4.2	      	Geron will make commercially reasonable efforts to maintain the
      Registration Statement and any post-effective amendment thereto filed
      under this Section 4 effective under the Act until the earliest of (i) the
      date that none of the Shares covered by such Registration Statement are
      issued and outstanding, (ii) the date that all of the Shares have been
      sold pursuant to such Registration Statement, (iii) the date MPI receives
      an opinion of counsel from Geron, which counsel shall be reasonably
      acceptable to MPI, that the Shares may be sold under the provisions of
      Rule 144 without limitation as to volume, (iv) the date that all Shares
      have been otherwise transferred to persons who may trade such shares
      without restriction under the Act, and Geron has delivered a new
      certificate or other evidence of ownership for such securities not bearing
      a restrictive legend, or (v) the date all Shares may be sold at any time,
      without volume or manner of sale limitations pursuant to Rule 144 or any
      similar provision then in effect under the Act in the opinion of counsel
      to Geron, which counsel shall be reasonably acceptable to
MPI.
	
            	 
	
            	4.3	
            	Geron, at its expense, shall furnish to MPI with respect to the
      Shares registered under the Registration Statement such reasonable number
      of copies of the Registration Statement, prospectuses and preliminary
      prospectuses in conformity with the requirements of the Act and such other
      documents as MPI may reasonably request, in order to facilitate the public
      sale or other disposition of all or any of the Shares by MPI, provided,
      however, that the obligation of Geron to deliver copies of prospectuses or
      preliminary prospectuses to MPI shall be subject to the receipt by Geron
      of reasonable assurances from MPI that MPI will comply with the applicable
      provisions of the Act and of such other securities or blue sky laws as may
      be applicable in connection with any use of such prospectuses or
      preliminary prospectuses.
	
            	 
	
            	4.4	
            	All fees, disbursements and out-of-pocket expenses and costs
      incurred by Geron in connection with the preparation and filing of the
      Registration Statement under Section 4.1 and in complying with applicable
      securities and Blue Sky laws (including, without limitation, all
      attorneys' fees of Geron) shall be borne by Geron. MPI shall bear the cost
      of fees and expenses of MPI’s counsel.
	
            	 
	
            	4.5	
            	Geron will advise MPI promptly after it shall receive notice or
      obtain knowledge of the issuance of any stop order by the Commission
      delaying or suspending the effectiveness of the Registration Statement or
      of the initiation of any proceeding for that purpose, and Geron will use
      its commercially reasonable efforts to prevent the issuance of any stop
      order or to obtain its withdrawal at the earliest possible moment if such
      stop order should be issued.
	
            	 
	
            	4.6	
            	With a view to making available to MPI the benefits of Rule 144 (or
      its successor rule) and any other rule or regulation of the Commission
      that may at the time permit MPI to sell the Shares to the public without
      registration, Geron covenants and agrees to make commercially reasonable
      efforts to: (i) make and keep public information available, as those terms
      are understood and defined in Rule 144, until the earliest of (A) such
      date as all of the Shares may be resold pursuant to Rule 144 or any other
      rule of similar effect or (B) such date as all of the Shares shall have
      been resold; and (ii) file with the Commission in a timely manner all
      reports and other documents required of Geron under the Act and under the
      Securities Exchange Act of 1934, as amended (the “Exchange
      Act”).

    

    

    
    

    
      	 	      	4.7	      	MPI
      will cooperate with Geron in all respects in connection with this
      Agreement, including timely supplying all information reasonably requested
      by Geron (which shall include all information regarding MPI and proposed
      manner of sale of the Shares required to be disclosed in any Registration
      Statement) and executing and returning all documents reasonably requested
      in connection with the registration and sale of the Shares and entering
      into and performing their obligations under any underwriting agreement, if
      the offering is an underwritten offering, in usual and customary form,
      with the managing underwriter or underwriters of such underwritten
      offering. Nothing in this Agreement shall obligate MPI to consent to be
      named as an underwriter in any Registration Statement.
	 
	5.	
            	INDEMNIFICATION.
	 
	 	
            	5.1	
            	Geron
      agrees to indemnify and hold harmless MPI (and each person, if any, who
      controls MPI within the meaning of Section 15 of the Act, and each officer
      and director of MPI) against any and all losses, claims, damages or
      liabilities (or actions or proceedings in respect thereof), joint or
      several, directly or indirectly based upon or arising out of (i) any
      untrue statement or alleged untrue statement of any material fact
      contained in the Registration Statement, any preliminary prospectus, final
      prospectus or summary prospectus contained therein or used in connection
      with the offering of the Shares, or any amendment or supplement thereto,
      or (ii) any omission or alleged omission to state a material fact required
      to be stated therein or necessary to make the statements therein not
      misleading; and Geron will reimburse each such indemnified party for any
      legal or any other expenses reasonably incurred by them in connection with
      investigating, preparing, pursuing or defending any such loss, claim,
      damage, liability, action or proceeding, except insofar as any such loss,
      claim, damage, liability, action, proceeding or expense (A) arises out of
      or is based upon an untrue statement or alleged untrue statement or
      omission or alleged omission made in the Registration Statement, any such
      preliminary prospectus, final prospectus, summary prospectus, amendment or
      supplement in reliance upon and in conformity with written information
      furnished to Geron by MPI or such other person expressly for use in the
      preparation thereof, (B) the failure of MPI to comply with its covenants
      and agreements contained in Sections 7.1 or 7.5.3 hereof or (C) any
      misstatement or omission in any prospectus that is corrected in any
      subsequent prospectus that was delivered to MPI prior to the pertinent
      sale or sales by MPI. Such indemnity shall remain in full force and
      effect, regardless of any investigation made by such indemnified party and
      shall survive the transfer of the Shares by MPI.
	 
	 	
            	5.2	
            	MPI
      agrees to indemnify and hold harmless Geron (and each person, if any, who
      controls Geron within the meaning of Section 15 of the Act, each officer
      of Geron who signs the Registration Statement and each director of Geron)
      from and against losses, claims, damages or liabilities (or actions or
      proceedings in respect thereof), joint or several, directly or indirectly
      based upon or arising out of, (i) any failure of MPI to comply with the
      covenants and agreements contained in Sections 7.1 and 7.5.3 hereof or
      (ii) any untrue statement of a material fact contained in the Registration
      Statement or any omission of a material fact required to be stated in the
      Registration Statement or necessary in order to make the statements in the
      Registration Statement not misleading if such untrue statement or omission
      was made in reliance upon and in conformity with written information
      furnished to Geron by on behalf of MPI specifically for use in preparation
      of the Registration Statement; provided, however, that MPI shall not be
      liable in any such case for (A) any untrue statement or omission in the
      Registration Statement, prospectus, or other such document which statement
      is corrected by MPI and delivered to Geron prior to the sale from which
      such loss occurred, (B) any untrue statement or omission in any prospectus
      which is corrected by MPI in any subsequent prospectus, or supplement or
      amendment thereto, and delivered to Geron prior to the sale or sales from
      which a loss or liability arose, or (C) any failure by Geron to fulfill
      any of its obligations under Section 5.1
hereof.

    

    

    
    

    
      	 	      	5.3	      	Promptly after receipt by any indemnified person of a notice of a
      claim or the beginning of any action in respect of which indemnity is to
      be sought against an indemnifying person pursuant to this Section 5, such
      indemnified person shall notify the indemnifying person in writing of such
      claim or of the commencement of such action, but the omission to so notify
      the indemnifying party will not relieve it from any liability which it may
      have to any indemnified party under this Section 5 (except to the extent
      that such omission materially and adversely affects the indemnifying
      party’s ability to define such action) or from any liability otherwise
      than under this Section 5. Subject to the provisions hereinafter stated,
      in case any such action shall be brought against an indemnified person,
      the indemnifying person shall be entitled to participate therein, and, to
      the extent that it shall elect by written notice delivered to the
      indemnified party promptly after receiving the aforesaid notice from such
      indemnified party, shall be entitled to assume the defense thereof, with
      counsel reasonably satisfactory to such indemnified person. After notice
      from the indemnifying person to such indemnified person of its election to
      assume the defense thereof, such indemnifying person shall not be liable
      to such indemnified person for any legal expense subsequently incurred by
      such indemnified person in connection with the defense thereof, provided,
      however, that if there exists or shall exist a conflict of interest that
      would make inappropriate, in the reasonable opinion of counsel to the
      indemnified person, for the same counsel to represent both the indemnified
      person and such indemnifying person or any affiliate or associate thereof,
      the indemnified person shall be entitled to retain its own counsel at the
      expense of such indemnifying person; provided, however, that no
      indemnifying person shall be responsible for the fees and expenses of more
      than one separate counsel (together with appropriate local counsel) for
      all indemnified parties. In no event shall any indemnifying person be
      liable in respect to any amounts paid in settlement of any action unless
      the indemnifying person shall have approved the terms of such settlement.
      No indemnifying person shall, without the prior written consent of the
      indemnified person, effect any settlement of any pending or threatened
      proceeding in respect of which any indemnified person is or could have
      been a party and indemnification could have been sought hereunder by such
      indemnified person, unless such settlement includes an unconditional
      release of such indemnified person from all liability on claims that are
      the subject matter of such proceeding.
	 
	 	
            	5.4	
            	The
      provisions of this Section 5 shall survive the termination of this
      Agreement.
	 
	6.	
            	REPRESENTATIONS AND
      ACKNOWLEDGEMENT OF GERON.
	 
	 	
            	Geron hereby represents, warrants and covenants to MPI as
      follows:
	 
	 	
            	6.1	
            	Organization, Good Standing
      and Qualification. Geron is a corporation duly organized, validly existing and in
      good standing under the laws of the State of Delaware and has all
      requisite corporate power and authority to carry on its business as now
      conducted and as presently proposed to be conducted. Geron is duly
      qualified to transact business and is in good standing as a foreign
      corporation in each jurisdiction in which the failure to so qualify would
      have a material adverse effect on its business or properties.
	 
	 	
            	6.2	
            	Authorization. All corporate action on the
      party of Geron, its officers, directors and stockholders necessary for the
      authorization, execution and delivery of this Agreement, the performance
      of all obligations of Geron hereunder and the authorization, issuance and
      delivery of the Shares has been taken or will be taken prior to the
      Closing, and this Agreement, when executed and delivered will constitute
      valid and legally binding obligations of Geron, enforceable against Geron
      in accordance with their terms, except as limited by applicable
      bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance
      and other laws of general application affecting enforcement of creditors’
      rights generally, as limited by laws relating to the availability of
      specific performance, injunctive relief or other equitable
    remedies.

    

    

    
    

    
      	 	
            	6.3	
            	Valid Issuance of Common
      Stock. The
      Shares, when issued, sold and delivered in accordance with the terms
      hereof for the consideration expressed herein, will be duly and validly
      authorized and issued, fully paid and nonassessable and free of
      restrictions on transfer other than restrictions on transfer under this
      Agreement and applicable state and federal securities laws.
	 
	 	
            	6.4	
            	Legal Proceedings and
      Orders.
      There is no action, suit, proceeding or investigation pending or
      threatened against Geron that questions the validity of this Agreement or
      the right of Geron to enter into this Agreement or to consummate this
      transactions contemplated hereby, nor is Geron aware of any basis for any
      of the forgoing. Geron is neither a party nor subject to the provisions of
      any order, writ, injunction, judgment or decree of any court or government
      agency or instrumentality that would affect the ability of Geron to enter
      into this Agreement or to consummate the transactions contemplated
      hereby.
	 
	7.	
            	REPRESENTATIONS AND
      ACKNOWLEDGMENTS OF MPI.
	 
	 	
            	MPI hereby represents, warrants, acknowledges and agrees
      that:
	 
	 	
            	7.1	
            	Investment. MPI is acquiring the Shares
      for MPI’s own account, and not directly or indirectly for the account of
      any other person. MPI is acquiring the Shares for investment and not with
      a view to distribution or resale thereof, except in compliance with the
      Act and any applicable state law regulating securities.
	 
	 	      	7.2	      	Access to
      Information. MPI has consulted with its own attorney, accountant, or
      investment advisor as MPI has deemed advisable with respect to the
      investment and has determined its suitability for MPI. MPI has had the
      opportunity to ask questions of, and to receive answers from, appropriate
      executive officers of Geron with respect to the terms and conditions of
      the transactions contemplated hereby and with respect to the business,
      affairs, financial condition and results of operations of Geron. MPI has
      had access to such financial and other information as is necessary in
      order for MPI to make a fully informed decision as to investment in Geron,
      and has had the opportunity to obtain any additional information necessary
      to verify any of such information to which MPI has had access. MPI
      acknowledges that neither Geron nor any of its officers, directors,
      employees, agents, representatives, or advisors have made any
      representation or warranty other than those specifically expressed
      herein.
	 
	 	
            	7.3	
            	Business and Financial
      Expertise.
      MPI further represents and warrants that it has such business or financial
      expertise as to be able to evaluate its investment in Geron and purchase
      of the Shares.
	 
	 	
            	7.4	
            	Speculative
      Investment. MPI acknowledges that the investment in Geron represented by the
      Shares is highly speculative in nature and is subject to a high degree of
      risk of loss in whole or in part; the amount of such investment is within
      MPI’s risk capital means and is not so great in relation to MPI’s total
      financial resources as would jeopardize the personal financial needs of
      MPI in the event such investment were lost in whole or in
  part.
	 
	 	
            	7.5	
            	Unregistered
      Securities. MPI acknowledges that:
	 
	 	
            	 	
            	7.5.1	      	MPI
      must bear the economic risk of investment for an indefinite period of time
      because the Shares have not been registered under the Act and therefore
      cannot and will not be sold unless they are subsequently registered under
      the Act or an exemption from such registration is available. Geron has
      made no agreements, covenants or undertakings whatsoever to register any
      of the Shares under the Act, except as provided in Section 4 above. Geron
      has made no representations, warranties or covenants whatsoever as to
      whether any exemption from the Act, including, without limitation, any
      exemption for limited sales in routine brokers’ transactions pursuant to
      Rule 144 under the Act, will become available and any such exemption
      pursuant to Rule 144, if available at all, will not be available unless:
      (i) a public trading market then exists in Geron’s common stock, (ii)
      Geron has complied with the information requirements of Rule 144, and
      (iii) all other terms and conditions of Rule 144 have been
      satisfied.
	 

    

    

    
    

    
      	
            	
            	
            	
            	7.5.2	      	Transfer of the Shares has not
      been registered or qualified under any applicable state law regulating
      securities and, therefore, the Shares cannot and will not be sold unless
      they are subsequently registered or qualified under any such act or an
      exemption therefrom is available. Geron has made no agreements, covenants
      or undertakings whatsoever to register or qualify any of the Shares under
      any such act. Geron has made no representations, warranties or covenants
      whatsoever as to whether any exemption from any such act will become
      available.
	
            	
            	
            	
            	
            	
            	 
	
            	
            	
            	
            	7.5.3	
            	MPI hereby certifies that it is
      an “Accredited Investor” as that term is defined in Rule 501 under the
      Act.
	
            	
            	
            	
            	 
	 	      	7.6	      	Authorization.
      MPI has
      full right, power, authority and capacity to enter into this Agreement and
      to consummate the transactions contemplated hereby and thereby and has
      taken all necessary action to authorize the execution, delivery and
      performance of this Agreement. Upon execution and delivery, this Agreement
      will constitute a valid and binding obligation of MPI enforceable against
      MPI in accordance with its terms, except as such enforceability may be
      limited by applicable bankruptcy, insolvency, reorganization, moratorium,
      fraudulent transfer, liquidation or similar laws relating to, or affecting
      generally, the enforcement of creditor's rights and remedies or by other
      equitable principles of general application from time to time in
      effect.
	 
	8.	
            	TAX ADVICE. MPI acknowledges that MPI
      has not relied and will not rely upon Geron or Geron’s counsel with
      respect to any tax consequences related to the ownership, purchase, or
      disposition of the Shares. MPI assumes full responsibility for all such
      consequences and for the preparation and filing of all tax returns and
      elections which may or must be filed in connection with the
    Shares.
	 
	9.	
            	NOTICES. Any notice or other
      communication required or permitted hereunder shall be in writing and
      shall be deemed to have been duly given on the date of delivery if
      delivered personally or by facsimile, or one day, not including Saturdays,
      Sundays, or national holidays, after sending if sent by national overnight
      delivery service, or five days, not including Saturdays, Sundays, or
      national holidays, after mailing if mailed by first class United States
      mail, certified or registered with return receipt requested, postage
      prepaid, and addressed as follows:

    

    
      	To Geron at:	Geron Corporation
	  	230 Constitution
    Drive
	 	Menlo Park, California
      94025
	  	Attention: Senior Director,
      Legal
	  	Telephone:       	(650) 473-7700
	  	Facsimile:	(650) 473-7750
	  
	To MPI at:	MPI Research,
Inc.
	  	54943 North Main
    Street
	  	Mattawan, MI
49071
	  	Telephone:
    269.668.3336
	  	Facsimile:
    269.668.4151

    

    

    
    

    
      	10.	
            	BINDING
      EFFECT.
      This Agreement shall be binding upon the heirs, legal representatives and
      successors of Geron and of MPI; provided, however, that MPI may not assign
      any rights or obligations under this Agreement.
	 
	11.	
            	GOVERNING
      LAW. This
      Agreement shall be governed by and construed in accordance with the laws
      of the State of California.
	 
	12.	      	INVALID
      PROVISIONS. In the event that any provision of this Agreement is found to be
      invalid or otherwise unenforceable by a court or other tribunal of
      competent jurisdiction, such invalidity or unenforceability shall not be
      construed as rendering any other provision contained herein invalid or
      unenforceable, and all such other provisions shall be given full force and
      effect to the same extent as though the invalid and unenforceable
      provision was not contained herein.
	 
	13.	
            	COUNTERPARTS. This Agreement may be
      executed in any number of identical counterparts, each of which shall be
      deemed an original, but all of which together shall constitute one and the
      same instrument.
	 
	14.	
            	AMENDMENTS. This Agreement or any
      provision hereof may be changed, waived, or terminated only by a statement
      in writing signed by the party against whom such change, waiver or
      termination is sought to be enforced.
	 
	15.	
            	FUTURE
      COOPERATION. Each of the parties hereto agrees to cooperate at all times from
      and after the date hereof with respect to all of the matters described
      herein, and to execute such further assignments, releases, assumptions,
      amendments of the Agreement, notifications and other documents as may be
      reasonably requested for the purpose of giving effect to, or evidencing or
      giving notice of, the transactions contemplated by this
    Agreement.
	 
	16.	
            	ENTIRE
      AGREEMENT.
      This Agreement and the Master Agreement as amended, including Amendment
      No. 7 and Amendment No. 8 thereto, constitute the entire agreement of the
      parties pertaining to the Shares and supersede all prior and
      contemporaneous agreements, representations, and understandings of the
      parties with respect thereto.

    

     

    *REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK* 

     

    *SIGNATURES
FOLLOW*

     

    

    
    

         IN WITNESS WHEREOF, the parties
hereto have executed this Common Stock Purchase Agreement as of the date first
above written. 

     

    
      	Geron Corporation
	  
	/s/ David L.
      Greenwood
	By:	David L.
Greenwood
	Title:       	Executive Vice
    President
	  	Chief Financial
    Officer
	  	Treasurer and
    Secretary
	  
	MPI Research,
Inc.
	  
	/s/ Paul
      Morgan
	By:	Paul Morgan
	Title:	Vice President and General
      Counsel

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]